Radiation sickness therapy set to begin human trials

The FDA has cleared Hollis-Eden to begin a Phase I trial of Neumene for radiation sickness. The initial study will focus on which dosages are likely to be effective in humans. The drug has worked in primate studies, reducing white blood cells and platelets in blood.

- read this story from the AP for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.